Volume 5, Supplement 2SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Howard M SandlerKenneth J PientaProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
Volume 5, Supplement 2SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
Volume 5, Supplement 2SupplementThe Role of the Urologist in Treating Patients with Hormone-Refractory Prostate CancerE David CrawfordChemotherapyHormone-refractory prostate cancerTrainingUrologistsReimbursement
Volume 5, Supplement 3SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Howard M SandlerKenneth J PientaProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
Volume 5, Supplement 3SupplementNeoadjuvant Therapy for Prostate Cancer: An Oncologist's PerspectiveElizabeth C KentMaha HA HussainProstate cancerChemotherapyRadical prostatectomyRadiotherapyHormonal therapyNeoadjuvant therapy
Volume 5, Supplement 3SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
Volume 6, Number 4Meeting ReviewsReport From The Society of Urologic OncologyHighlights From The Fourth Annual Meeting of the Society of Urologic Oncology, December 5-6, 2003Oleg ShvartsJohn S LamArie S BelldegrunRenal cell carcinomaChemotherapyLaparoscopyUrologic oncologyProstatectomy
Volume 7, Number 1Meeting ReviewsProstate Cancer Update: 2004Stephen J FreedlandAlan W PartinProstate cancerChemotherapyHigh-intensity focused ultrasoundDocetaxelFinasterideDutasteride
Volume 8, Number 2Review ArticlesTreatment of Upper Tract Urothelial Carcinoma: A Review of Surgical and Adjuvant TherapyTreatment ReviewChristopher R PorterKalyan C LatchamsettyUpper tract urothelial carcinoma is a disease entity that has not been as extensively studied and reviewed as carcinoma of the bladder. Recent advances in technology and adjuvant therapy have changed the treatment armamentarium of oncologists and urologists. A literature review was conducted that focused on newer surgical techniques, including laparoscopy and endoscopic management of upper tract disease. Adjuvant therapy including immunotherapy, chemotherapy, and radiation is also reviewed. Nephroureterectomy with removal of a bladder cuff still remains the gold standard of treatment. However, laparoscopic nephroureterectomy is quickly becoming popular, with equivalent recurrence rates. Because of the relatively recent introduction of laparoscopy into the urologic field, long-term data with respect to recurrence rates and survival rates are not yet available. Immunotherapy has also shown promise, but with higher recurrence rates than surgery. Chemotherapy and radiation also show some improvement in recurrence rates, but there have been no randomized, prospective trials. Endoscopic management is acceptable in patients with severe medical comorbidities or solitary kidneys but requires rigorous and close follow-up. Adjuvant therapy with either chemotherapy or radiation is still debated but does offer some improvement in disease-specific survival. Randomized, prospective, placebo-controlled studies are required but are difficult to perform because of the relatively low incidence and prevalence of this disease. [Rev Urol. 2006;8(2):61-70]ImmunotherapyChemotherapyUrothelial carcinomaRadiation
Volume 9, Supplement 2Review ArticlesTreatment Options for Hormone-Refractory Prostate CancerAndrogen-Independent Prostate CancerSam S ChangHormone-refractory prostate cancer is a disease that includes a variety of patients and represents a treatment dilemma for the practicing physician. Because of the diversity of this group, management strategies must be targeted to the clinical situations of the individual patients and their wishes. This article outlines a logical progression of treatment choices that currently exist in this rapidly evolving field, and the landmark chemotherapy trials involving docetaxel (SWOG 9916 and TAX 327) are reviewed. Although significant progress has been made in understanding and treating hormonerefractory prostate cancer, current treatments do not yet provide a cure, and important clinical trials continue to recruit patients. [Rev Urol. 2007;9(suppl 2):S13-S18]ChemotherapyHormone-refractory prostate cancerAndrogen-independent prostate cancerTaxanes